Research into the AMP family -- particularly in regards to their mechanism of action -- has been ongoing for nearly 20 years. Despite sustained interest, treatments derived or utilizing AMPs have not been widely adopted for clinical use for several reasons. One, drug candidates from AMPs have a narrow window of bioavailability, because peptides are quickly broken down by proteases. Two, peptide drugs are more expensive than small molecule drugs to produce, which is problematic since peptide drugs must be given in large doses to counter rapid enzymatic breakdown. These qualities also limit routes of administration, typically to injection, infusion, or slow release therapy.
Cathelicidin
Fibrinolysin
Peroxin-7
Kaliotoxin
Staphylotoxin
Cyanotoxin
Eoxin
Tetanospasmin